A Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Enrolling By Invitation
18 years - 99 years
All
Phase
2
45 participants needed
1 Location
Brief description of study
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-0482, MK-5890, MK-4830) in combination with pembrolizumab based therapy in patients with PD-(L)1 refractory NSCLC in a rolling-arm design
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Non-small Cell Lung Cancer,NSCLC
-
Age: 18 years - 99 years
-
Gender: All
Male or Female, Age 18 or older, A histologically confirmed diagnosis of squamous or nonsquamous NSCLC
Updated on
01 Aug 2024.
Study ID: 851175
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
